ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
438 articles with ImmunoGen Inc.
-
Debiopharm Enters The Field Of Antibody-Drug Conjugates Through Acquisition Of Phase II Asset From ImmunoGen
5/24/2017
-
ImmunoGen Announces New Clinical Data With Mirvetuximab Soravtansine In Ovarian Cancer To Be Presented At 2017 ASCO Annual Meeting
5/18/2017
-
ImmunoGen Reports Recent Progress And First Quarter 2017 Operating Results
5/5/2017
-
ImmunoGen Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer
5/1/2017
-
ImmunoGen Announces Conference Call To Discuss Its First Quarter 2017 Financial Results
4/21/2017
-
ImmunoGen Presents Phase I Biopsy Expansion Cohort Data At The Society Of Gynecologic Oncology Annual Meeting
3/13/2017
-
ImmunoGen Announces Presentations At AACR Annual Meeting
3/2/2017
-
Why ImmunoGen Investors are Waiting on Bated Breath to Move "FORWARD"
2/22/2017
-
ImmunoGen Reports Recent Progress And Operating Results For Six-Month Period And Quarter Ended December 31, 2016
2/17/2017
-
ImmunoGen Announces First Patient Dosed In FORWARD I Phase 3 Study Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer
1/27/2017
-
ImmunoGen Announces Conference Call To Discuss Its Results For Six-Month Period And Quarter Ended December 31
1/26/2017
-
ImmunoGen Release: Biotech Announces Departure Of Sandra Poole
1/24/2017
-
ImmunoGen CEO Sees Potential in Company’s Lead ADC Product
1/18/2017
-
ImmunoGen Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results In Platinum-Resistant Ovarian Cancer Published In The Journal Of Clinical Oncology
12/28/2016
-
ImmunoGen Release: Preclinical Data On IMGN632, A Novel CD123-Targeting ADC, Presented At American Society of Hematology Annual Meeting
12/6/2016
-
ImmunoGen To Present Preclinical Data Highlighting Potential Of Combining Mirvetuximab Soravtansine With An Immune Checkpoint Inhibitor At SITC 2016 Annual Meeting
11/11/2016
-
ImmunoGen Reports Financial Results For Quarter Ended September 30 And Reviews Business Highlights
10/28/2016
-
ImmunoGen Announces Conference Call To Discuss Its Financial Results For Quarter Ended September 30
10/14/2016
-
Struggling ImmunoGen Eliminates 17% of Workforce After Strategic Review
10/3/2016
-
ImmunoGen Announces Departure Of Chief Development Officer
8/9/2016